With a CAGR of 11.6% from 2020 to 2027, the market for drugs for late-stage chronic kidney disease, which is divided by product type, indication, distribution channel, and geography, was valued at US$ 4,680.0 Mn in 2019 and is anticipated to grow to US$ 11,096.9 Mn by 2027.